Clinical trials
Phase 2 Leukemia trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 7 |
| Unknown status | 5 |
| Completed | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2 |
| Shanghai Jiao Tong University School of Medicine | 2 |
| AbbVie | 1 |
| BeiGene | 1 |
| Bristol-Myers Squibb | 1 |
| Chi Kong Li | 1 |
| Daiichi Sankyo | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Novartis Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia | 17 |
| Leukemia, Myeloid, Acute | 3 |
| Recurrence | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 |
| Lymphoma | 2 |
| Philadelphia Chromosome | 2 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Graft vs Host Disease | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.